NDLI: Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation

Content Provider	PubMed Central
Author	Philipose, Sonia Konya, Viktoria Lazarevic, Mirjana Pasterk, Lisa M. Gunther, Marsche Frank, Sasa Peskar, Bernhard A. Heinemann, Akos Schuligoi, Rufina
Editor	Schulz, Christian
Copyright Year	2012
Abstract	The use of the lipid lowering agent niacin is hampered by a frequent flush response which is largely mediated by prostaglandin (PG) D2. Therefore, concomitant administration of the D-type prostanoid (DP) receptor antagonist laropiprant has been proposed to be a useful approach in preventing niacin-induced flush. However, antagonizing PGD2, which is a potent inhibitor of platelet aggregation, might pose the risk of atherothrombotic events in cardiovascular disease. In fact, we found that in vitro treatment of platelets with laropiprant prevented the inhibitory effects of PGD2 on platelet function, i.e. platelet aggregation, Ca2+ flux, P-selectin expression, activation of glycoprotein IIb/IIIa and thrombus formation. In contrast, laropiprant did not prevent the inhibitory effects of acetylsalicylic acid or niacin on thrombus formation. At higher concentrations, laropiprant by itself attenuated platelet activation induced by thromboxane (TP) and E-type prostanoid (EP)-3 receptor stimulation, as demonstrated in assays of platelet aggregation, Ca2+ flux, P-selectin expression, and activation of glycoprotein IIb/IIIa. Inhibition of platelet function exerted by EP4 or I-type prostanoid (IP) receptors was not affected by laropiprant. These in vitro data suggest that niacin/laropiprant for the treatment of dyslipidemias might have a beneficial profile with respect to platelet function and thrombotic events in vascular disease.
Related Links	http://dx.doi.org/10.1371/journal.pone.0040222
Starting Page	40222
File Format	PDF
ISSN	19326203
e-ISSN	19326203
Journal	PLoS ONE
Issue Number	8
Volume Number	7
Language	English
Publisher	Public Library of Science
Publisher Date	2012-08-01
Access Restriction	Open
Rights Holder	Public Library of Science
Subject Keyword	Biochemistry, Genetics and Molecular Biology(all) Agricultural and Biological Sciences(all) Medicine(all) Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Multidisciplinary

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation

Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation

Laropiprant attenuates EP3and TP prostanoid receptor-mediated thrombus formation

EMILIN2 Regulates Platelet Activation, Thrombus Formation, and Clot Retraction

Inverse Agonist and Pharmacochaperone Properties of MK-0524 on the Prostanoid DP1 Receptor

Inhibition of EP4 Signaling Attenuates Aortic Aneurysm Formation

Activation of PERK Signaling Attenuates Aβ-Mediated ER Stress

Inhibition of Hb Binding to GP1bα Abrogates Hb-Mediated Thrombus Formation on Immobilized VWF and Collagen under Physiological Shear Stress

Apolipoprotein A-I Attenuates Palmitate-Mediated NF-κB Activation by Reducing Toll-Like Receptor-4 Recruitment into Lipid Rafts

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation

Similar Documents

Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation

Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation

Laropiprant attenuates EP3and TP prostanoid receptor-mediated thrombus formation

EMILIN2 Regulates Platelet Activation, Thrombus Formation, and Clot Retraction

Inverse Agonist and Pharmacochaperone Properties of MK-0524 on the Prostanoid DP1 Receptor

Inhibition of EP4 Signaling Attenuates Aortic Aneurysm Formation

Activation of PERK Signaling Attenuates Aβ-Mediated ER Stress

Inhibition of Hb Binding to GP1bα Abrogates Hb-Mediated Thrombus Formation on Immobilized VWF and Collagen under Physiological Shear Stress

Apolipoprotein A-I Attenuates Palmitate-Mediated NF-κB Activation by Reducing Toll-Like Receptor-4 Recruitment into Lipid Rafts

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation